Everen Declares $350 Million Dividend
27.3.2025 17:30:00 EET | Business Wire | Press release
Everen Limited today announced a dividend of $350 million, affirming Everen’s commitment to delivering value to its shareholders.
The decision by Everen’s Board of Directors was announced at the Company’s Annual General Meeting (AGM) in Bermuda on Thursday, March 20, 2025. The dividend is payable on or before September 30, 2025 to shareholders of record on March 20, 2025.
Robert Foskey, President & CEO of the Everen Group, commented: “Everen continues to go from strength to strength with an exceptional year in 2024, both from a financial and operational point of view. We closed out the year with some of our best-ever results, driven by strong investment performance and modest incurred losses.”
Addressing Everen’s shareholders, Mr. Foskey said: “For the twelfth year in a row, we are pleased to once again declare a substantial dividend. Cumulatively, over the past 12 years, we have returned over $3.8 billion in dividends to our shareholders. Everen’s consistent financial returns, coupled with our disciplined approach to capital management, puts us in a solid position to return value to our shareholders year after year.”
Mr. Foskey also noted that the Company closed out the year with the highest number of members since 2005, with five new members joining in 2024, bringing total membership to 72 members worldwide.
At the meeting, shareholders elected Everen’s Board of Directors who will serve until the March 2026 AGM. Mr. John Weisner was elected as Chair and Mr. Brian Mullen was elected Vice Chair.
The AGM followed a two-day Shareholder Conference, March 18-19, at the Hamilton Princess in Bermuda. The Everen Group’s flagship conference is Bermuda’s largest energy insurance event with more than 90 energy company representatives attending from the Americas, Europe and as far afield as Australia, New Zealand and Japan. Experts in energy, earth systems science, climate change litigation and risk management spoke on the latest trends and emerging issues in the energy sector, including carbon capture, energy transition and climate attribution.
About Everen Group
The Everen Group – a group of leading energy insurance companies based in Bermuda – includes two distinct operating companies providing complementary products: Everen and Everen Specialty. Everen is the largest energy insurance mutual company in the world, operating for over 50 years and acting as a pure mutual owned by its member shareholders. Its underwriting is 100% supported by its own balance sheet with no third-party capital and it offers up to $450 million of per occurrence limits. Everen Specialty is an industry-owned commercial (re)insurer offering property and casualty insurance and reinsurance for members and non-members. Everen Specialty also has a subsidiary, OCIL Specialty, Ltd (OSL), writing U.S. surplus lines business through OSL Insurance Services (OISI), a managing general agent based in Houston, Texas.
For further information about the Everen Group, please visit www.everengroup.bm
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327830406/en/
Contacts
For inquiries regarding this press release, please contact:
Elizabeth Deacon, Communications Manager on elizabeth.deacon@everengroup.bm
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom